Implantable biological tissue and process for preparation thereof

• US 4,648,881 A
• Filed: 11/29/1982
• Issued: 03/10/1987
• Est. Priority Date: 03/23/1982
• Status: Expired due to Term

• Current Assignee: Edwards Lifesciences Corporation
• Original Assignee: American Hospital Supply Corp. (Baxter International Inc.)
• Inventors: Carpentier, Alain, Carpentier, Sophie, Nashef, Aws S.
• Primary Examiner(s): NOT, DEFINED
• Assistant Examiner(s): Beaucage, Gregory
• Application Number:
  US06/445,345
• Time in Patent Office: 1,562 Days
• Field of Search: 3/1, 3/1.4, 3/1.5, 435/1, 8/94.11, 623/1, 623/2, 623/11, 623/66
• US Class Current: 128/898
• CPC Class Codes: A61F 2/2412 with soft flexible valve members, e.g. tissue valves shaped like natural valves check valves with flexible valve members in general F16K15/14
• CPC Class Codes: A61L 2400/02 Treatment of implants to prevent calcification or mineralisation in vivo
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: Y10S 623/918 Heart
• CPC Class Codes: Y10S 623/92 Method or apparatus for preparing or treating prosthetic
• CPC Class Codes: Y10S 623/922 Heart

Abstract

A process for the preparation of implantable biological tissue, and in particular bioprosthetic heart valves, which are prone to calcification after implantation. The process includes treatment of tissue with solutions prior to implantation which have been found effective in reducing calcification of the implanted tissue.

Claims

1. A process for treating biological tissue prior to implantation which comprises the steps of:

a. contacting said tissue with a phosphate-deficient solution, said solution having a level of phosphate decreased to an amount effective in reducing calcification of said tissue after implantation, said solution further being non-destructive or non-destabilizing to said tissue; and

b. maintaining the tissue in contact with such a phosphate-deficient solution during fixation, sterilization, and post-fixation storage of said tissue.

2. The process of claim 1 wherein the phosphate-deficient solution is substantially phosphate-free.

3. The process of claim 1 wherein the biological tissue is maintained in the phosphate-deficient solution during shipping.

4. The process of claim 1 wherein the biological tissue is maintained in the phosphate-deficient solution from a time subsequent to extraction from its host to a time immediately prior to implantation.

5. The process of claim 1 wherein the phosphate-deficient solution is non-interfering with the tissue stabilization process.

6. The process of claim 5 wherein the phosphate-deficient solution comprises a buffer.

7. The process of claim 6 wherein the phosphate-deficient buffer is non-reactive with glutaraldehyde.

8. The process of claim 2 wherein the substantially phosphate-free solution comprises saline.

9. The process of claim 6 wherein the phosphate-deficient solution is selected from the group consisting of borate, carbonate, bicarbonate, cacodylate, HEPES, MOPS, and PIPES.

10. The process of claim 2 wherein the substantially phosphate-free solution comprises HEPES-buffered-saline.

11. The process of claim 1, 2, 4, 6, or 10 wherein the biological tissue is used in the preparation of a heart valve.

12. The process of claim 11 wherein the phosphate-deficient solution comprises a buffer having a buffering capacity effective in maintaining a tissue-stabilizing pH.

13. The process of claim 12 wherein the buffer is HEPES and has a concentration from about 0.001 to about 0.10M.

14. The process of claim 12 wherein the buffer is HEPES and has a concentration from about 0.002 to about 0.050M.

15. The process of claim 1 which further comprises the step of contacting said tissue with an amount of a calcium-binding competing divalent cation effective in reducing calcification of the tissue after implantation.

16. The process of claim 15 wherein the divalent cation is a magnesium ion or salt thereof.

17. The process of claim 16 wherein the magnesium salt is selected from the group consisting of MgCl₂, MgSO₄, and MgCO₃.

18. The process of claim 16 wherein the magnesium salt is MgCl₂.

19. The process of claim 15, 17 or 18 wherein the tissue is treated with an amount of the divalent cation sufficient to saturate the tissue.

20. The process of claim 15, 17 or 18 wherein the biological tissue is used in the preparation of a heart valve.

21. The process of claim 18 wherein the tissue is used in the preparation of a heart valve and the concentration of magnesium chloride MgCl₂ is about 0.26 weight percent.

22. A method of increasing the durability of implantable biological tissue which comprises the steps of:

a. reducing the amount of phosphate in contact with said tissue with a phosphate-deficient solution, said solution having a level of phosphate decreased to an amount effective in reducing calcification of said tissue after implantation, said solution further being non-destructive or non-destabilizing to said tissue; and

b. maintaining the tissue in contact with such a phosphate-deficient solution during fixation, sterilization, and post-fixation storage of said tissue.

23. The method of claim 22 wherein the phosphate-deficient solution is substantially phosphate-free.

24. The method of claim 22, wherein the tissue was previously treated with a phosphate-containing solution during shipping.

25. The method of claim 24 wherein the phosphate-deficient solution comprises a buffer.

26. The method of claim 23 wherein the substantially phosphate-free solution comprises saline.

27. The method of claim 25 wherein the phosphate-deficient solution is selected from the group consisting of borate, carbonate, bicarbonate, cacodylate, HEPES, MOPS, and PIPES.

28. The method of claim 23 wherein the substantially phosphate-free solution comprises HEPES-buffered-saline.

29. The method of claim 22, 23, 25 or 26 wherein the biological tissue is used in the preparation of a heart valve.

30. The method of claim 29 wherein the phosphate-deficient solution comprises a buffer having a buffering capacity effective in maintaining a tissue-stabilizing pH.

31. The method of claim 30 wherein the buffer is HEPES and has a concentration from about 0.001M to about 0.1M.

32. The method of claim 22 which further comprises the step of contacting said tissue with an amount of a calcium-binding competing divalent cation effective in reducing calcification of the tissue after implantation.

33. The method of claim 22 wherein the divalent cation is a magnesium ion or salt thereof.

34. The method of claim 33 wherein the magnesium salt is selected from the group consisting of MgCl₂, MgSO₄ and MgCO₃.

35. The method of claim 33 wherein the magnesium salt is MgCl₂.

36. The method of claim 32, 33, or 35 wherein the tissue is treated with an amount of the divalent cation sufficient to saturate the tissue.

37. The method of claim 32, 33, or 35 wherein the biological tissue is used in the preparation of a heart valve.

38. The method of claim 35 wherein the tissue is used in the preparation of a heart valve and the concentration of magnesium chloride MgCl₂ is about 0.26 weight percent.